Bajaj Healthcare Limited (BHL), a leading manufacturer of APIs, Intermediates and Formulations, has announced the appointment of Dr. Mohammed Jaweed Mukarram as an Advisor in the Research and Development division, specializing in Active Pharmaceutical Ingredients (APIs).
BHL has appointed Dr. Mohammed Jaweed Mukarram as an Advisor in the Research and Development division, specializing in Active Pharmaceutical Ingredients (APIs). He is holding 45 years of Research Experience (including Ph.D as well as of post Doctoral). His extensive knowledge and expertise make him a valuable addition to our team.
Commenting on the above business update, Mr. Anil Jain, Joint Managing Director, Bajaj Healthcare said: "I am delighted to inform you that the Company has appointed Dr. Mohammed Jaweed Mukarram as an Advisor in the Research and Development division, specializing in Active Pharmaceutical Ingredients (APIs). Dr. Mohammed Jaweed Mukarram brings with him a wealth of experience spanning an impressive 45 years in the field of Research and Development (including Ph.D as well as of post Doctoral). His extensive knowledge and expertise make him a valuable addition to our team.
Dr. Mohammed Jaweed Mukarram, holds both a Ph.D. and a post-Doctoral degree, underscoring his deep academic background and his commitment to advancing the field. With his remarkable credentials, we are confident that he will play a pivotal role in driving our research initiatives forward.
Dr. Mohammed Jaweed Mukarram, illustrious career includes significant roles at esteemed organizations, such as Sr. Associate Director at Wockhardt, where he spearheaded the Chemical Research Division. Over the years, he has made a mark in the industry by filing a noteworthy 156 patent applications. His expertise has led to the successful handling of over 70 bulk drugs and intermediates, boasting an impressive 35 US Drug Master File (DMF) filings to date." |
